NEW YORK – Seattle-based Silverback Therapeutics on Wednesday announced that it had begun dosing patients in a Phase I clinical trial evaluating SBT6050, an agent comprising a TLR8 agonist conjugated to a HER2-directed monoclonal antibody.
The multicenter trial, which plans to enroll roughly 210 participants, will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of the agent as a treatment for patients with advanced HER2-expressing solid tumors.